Press ESC to close

Peptide Lab App Log in Articles News Guide Products
More Peptide Tracker Calculator Best Calculators Peptide Statistics Contact Newsletter
Français English Deutsch Español Português العربية Italiano Polski 한국어 日本語 中文 Русский
GnRH
Decapeptide

Gonadorelin

Gonadotropin-Releasing Hormone (GnRH, LHRH), synthetic decapeptide

1182.31 g/mol Molecular Weight
C₅₅H₇₅N₁₇O₁₃ Formula
Formerly FDA-approved as a human medicine; no branded human gonadorelin product is currently marketed in the United States Status
pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH₂ (10 amino acids, identical to native human GnRH)
Gonadorelin Photo: Thirdman

What is gonadorelin, and how does it differ from GnRH analogues?

Gonadorelin is the pharmaceutical name for synthetic gonadotropin-releasing hormone (GnRH), the ten amino acid peptide that hypothalamic neurons release to control the entire reproductive axis. The sequence, pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH₂, is identical to the human hormone. That distinction matters more than it sounds: gonadorelin is not a redesigned molecule but a copy of the signal the body already uses.

The hormone itself was isolated and sequenced from porcine hypothalamic extracts by Schally and colleagues in 1971, work that showed a single decapeptide triggers release of both luteinizing hormone (LH) and follicle-stimulating hormone (FSH). That discovery opened two completely different pharmaceutical directions. One led to gonadorelin, the unmodified hormone. The other led to the GnRH agonists such as leuprorelin, triptorelin and goserelin, which are deliberately modified at positions 6 and 10 to resist enzymatic breakdown.

Those modifications change everything clinically. Native gonadorelin disappears from plasma within minutes, so it can only mimic physiology if it is delivered in repeated short bursts. Long-acting agonists persist for weeks, which floods the pituitary continuously and ultimately suppresses it, the reason they are used in prostate cancer, endometriosis and precocious puberty. Same receptor, opposite clinical outcome, and the difference is pharmacokinetics rather than receptor biology.

Gonadorelin also sits downstream of a regulator that has attracted its own research literature. GnRH neurons are driven largely by kisspeptin signaling in the arcuate nucleus, which is why kisspeptin is studied as a way to act one step higher in the same axis. Gonadorelin acts at the pituitary gonadotrope; kisspeptin acts on the neurons that set the rhythm.

This article is educational only and does not contain administration guidance. Nothing here should be used in place of advice from a qualified healthcare professional.

How does gonadorelin act on the pituitary?

Gonadorelin binds GnRH receptors on pituitary gonadotrope cells, which signal through a Gq coupled pathway to release stored LH and FSH into the circulation. LH then stimulates Leydig cells in men and drives the ovulatory surge in women, while FSH supports Sertoli cell function and spermatogenesis in men and follicular growth in women. The downstream effect of gonadorelin is therefore indirect: it raises gonadotropins, and the gonads respond.

The decisive variable is timing. In 1978, Belchetz, Plant, Nakai, Keogh and Knobil showed in rhesus monkeys with hypothalamic lesions that continuous infusion of GnRH failed to restore gonadotropin secretion, while intermittent delivery once per hour reestablished it. Continuous exposure in animals whose secretion had already been restored produced desensitization and down regulation of the release machinery. The authors attributed the difference to the pattern of delivery rather than the total quantity of hormone, and that single finding still explains why GnRH based drugs can either stimulate or suppress.

Pharmacokinetics make this pattern unavoidable. In human subjects, Pimstone and colleagues measured the plasma disappearance of exogenous GnRH and reported a rapid initial half disappearance time of roughly 5.5 to 8 minutes in healthy volunteers, with prolonged clearance in renal failure and little change in moderate liver dysfunction, pointing to the kidney as an important route of elimination. A peptide that vanishes this quickly cannot produce a sustained hormonal state on its own.

Physiologically, hypothalamic GnRH pulses occur roughly every 60 to 120 minutes in reproductive adults, and the pituitary interprets that frequency as information. Faster pulse frequencies favor LH, slower frequencies favor FSH, and the absence of pulses produces quiescence. Reproducing that signal pharmacologically historically required a programmable pump, which is exactly what the approved pulsatile products used.

This is also why comparisons with growth hormone releasing peptides can mislead. Sermorelin acts on a different axis with different feedback dynamics, and the pulse frequency dependence that dominates GnRH biology has no exact equivalent there.

Which gonadorelin medicines were approved, and what happened to them?

Two distinct human products carried gonadorelin in the United States, and they used it in opposite ways. Factrel (gonadorelin hydrochloride, NDA 018123) was approved in the early 1980s as a diagnostic agent for evaluating pituitary gonadotropic function. A single injection was given and LH was measured over the following hour, which told clinicians whether the gonadotropes could respond. Drugs@FDA now lists Factrel as discontinued, with no generic equivalents.

Lutrepulse (gonadorelin acetate, NDA 019687) was approved on October 10, 1989, with orphan designation, for inducing ovulation in women with primary hypothalamic amenorrhea. It was not a simple injection product: it was delivered through a programmable pump that released the peptide at fixed intervals to reproduce hypothalamic pulses. Lutrepulse was later withdrawn from the US market, and no FDA-approved gonadorelin product for ovulation induction is marketed in the United States today.

The pulsatile concept did not disappear elsewhere. Gonadorelin acetate remains nationally authorized in parts of the European Union under the name Lutrelef, indicated for substitution of endogenous GnRH deficiency and administered with a dedicated pulsatile pump system. Ferring also ran a multicenter, double-blind, randomized, placebo-controlled study (NCT01976728) testing subcutaneous pulsatile GnRH delivered by an OmniPod pump for ovulation induction in women with primary amenorrhea and hypogonadotropic hypogonadism, which shows the delivery problem was still being engineered well into the 2010s.

Diagnostic availability has become patchy in several countries, and the pediatric endocrinology literature now routinely describes agonist-based stimulation tests, using triptorelin, as substitutes where gonadorelin can no longer be sourced reliably. Published comparisons generally report that the classic GnRH test produces a faster and higher LH peak, while agonist tests give delayed and lower peaks, so the substitution is pragmatic rather than ideal.

In the United Kingdom, a gonadorelin injection remains licensed, indicated for evaluating the functional capacity and response of the anterior pituitary gonadotropes. Its licensed use is diagnostic, not therapeutic.

What does the human evidence on gonadorelin actually show?

The real clinical evidence base for gonadorelin sits in reproductive endocrinology, where pulsatile GnRH was used to replace a missing hypothalamic signal in people who genuinely lacked it. That population is narrow, and the results in it are strong.

In the largest published single-center series, Quaas and colleagues reviewed 25 years of pulsatile GnRH pump therapy for infertile women with functional hypothalamic amenorrhea, covering 66 patients, 82 treatments and 212 cycles between 1996 and 2020. The ovulation rate per cycle was 96%, and ovulation was monofollicular in 75% of cycles. The authors concluded that the pulsatile GnRH pump represented a safer and more physiologic alternative to ovulation induction with injectable gonadotropins, citing high cumulative live birth rates alongside low multiple gestation rates and normal newborn birth weight.

In men, pulsatile GnRH has been compared with combined gonadotropin therapy for inducing spermatogenesis in gonadotropin deficiency. A retrospective cohort published in Endocrine Practice in 2024 by Zhang and colleagues at Peking Union Medical College Hospital reported that pulsatile GnRH therapy was associated with better spermatogenic outcomes, including earlier appearance of sperm, than hMG and hCG therapy in patients with pituitary stalk interruption syndrome. In idiopathic hypogonadotropic hypogonadism and Kallmann syndrome, other published comparisons have found no significant difference between the two approaches in time to sperm appearance or pregnancy rates.

Mechanistic human work exists as well. A completed Massachusetts General Hospital study (NCT00493961) examined the effects of seven days of exogenous pulsatile GnRH on the pituitary gonadal axis in hypogonadotropic hypogonadal subjects, the kind of physiology study that defines how the axis responds rather than whether a product helps patients.

Two features unify all of this evidence. First, the participants had a deficient or absent endogenous GnRH signal. Second, the peptide was delivered by pump at programmed intervals. Neither condition applies to a healthy adult with an intact hypothalamus, which is the central interpretive problem discussed below.

Why are testosterone clinics interested in gonadorelin instead of hCG?

The shift has a regulatory origin rather than a scientific one. Men on exogenous testosterone suppress their own LH and FSH, and clinicians who want to maintain testicular function alongside therapy have historically reached for human chorionic gonadotropin (hCG), which acts as an LH analogue at the Leydig cell. The American Urological Association guideline on testosterone deficiency addresses this directly, advising that testosterone monotherapy should not be prescribed for men interested in current or future fertility and describing hCG among the options for men with fertility concerns.

On March 23, 2020, hCG and several other products transitioned from being regulated as drugs to being licensed as biological products under section 351 of the Public Health Service Act. The FDA's notice to compounders set out the consequence plainly: transitioning biological products are no longer eligible for the compounding exemptions in sections 503A and 503B of the FD&C Act. Compounded hCG, which had been a common and inexpensive route for men's health prescribing, largely vanished from that channel.

The effect was measured. Borgert and colleagues, publishing in Sexual Medicine in 2023, identified 81 FDA-registered 503B outsourcing facilities approved to compound hCG and FSH, contacted all of them with a 92.6% response rate, and found that only five supplied hCG. Of the facilities that had stopped, six of eight cited the 2020 regulatory change as the reason. Branded hCG supply has also been subject to allocation and shortage reporting, tracked publicly in the ASHP drug shortage database.

Gonadorelin filled that gap for a specific legal reason: it is a small synthetic peptide, not a biological product, and it is the active ingredient of previously approved human drugs, so compounding pharmacies have continued to prepare it against patient-specific prescriptions. Clinics frequently present it as a more physiologic choice because it acts upstream at the pituitary rather than bypassing it.

That argument is coherent on paper and untested in practice. The pharmacology section above is the reason for caution: a peptide cleared in minutes, given at intervals far longer than a hypothalamic pulse, is not obviously reproducing the signal it is meant to replace. Readers comparing options in this space may also want the broader context in our overview of peptides discussed for testosterone support.

What do the studies not show about gonadorelin?

Separating what is documented from what is inferred is the most useful thing a guide can do here, because the gap is unusually wide.

There is no published randomized controlled trial showing that gonadorelin preserves testicular volume, maintains intratesticular testosterone, protects spermatogenesis or improves symptoms in men receiving exogenous testosterone. The human literature that exists concerns people with a deficient endogenous GnRH signal, and it used pump-delivered pulses. Transferring those results to men with an intact hypothalamus who are being suppressed by testosterone is an extrapolation across both population and delivery method, and extrapolation is not evidence.

There is also no head-to-head clinical trial comparing gonadorelin with hCG for any men's health endpoint. Claims that one is superior to the other, in either direction, currently rest on mechanism and clinical impression rather than comparative data. Nothing in the verified literature establishes equivalence either.

Long-term safety data in non-deficient adults do not exist. The historical safety record comes from single diagnostic injections and from supervised pump therapy in fertility clinics, often over weeks to months with monitoring of follicular development or sperm parameters. Repeated self-administration over years in healthy men has not been studied, so the honest statement is that long-term risk is unquantified rather than low.

Finally, the desensitization question has not been resolved for real-world use patterns. The 1978 primate work shows that the pituitary distinguishes intermittent from continuous exposure, but it does not tell us what happens with intermediate patterns, and no published human study has characterized receptor responsiveness under the administration patterns now common outside clinical trials. That is an open question, not a settled reassurance, and it should be discussed with a physician who can monitor LH, FSH, testosterone and semen parameters rather than inferred from a mechanism diagram.

What is known about the tolerability and risks of gonadorelin?

The documented safety profile is drawn from two settings: short diagnostic use, and supervised pulsatile therapy in fertility medicine. Within those settings, the peptide has generally been considered well tolerated, with reported effects including headache, nausea, lightheadedness, abdominal discomfort and flushing, usually transient.

Hypersensitivity is the serious concern. The UK summary of product characteristics for the licensed diagnostic preparation lists hypersensitivity reactions as rare and also notes antibody formation as a rare finding. Case reports confirm that severe reactions occur: Akın and colleagues described anaphylaxis following intravenous gonadorelin acetate during an LHRH stimulation test in an 8 year old girl with central precocious puberty, reported as the first such pediatric case. Rare does not mean impossible, and anaphylaxis is the reason stimulation testing is performed in supervised settings.

Antibody formation against GnRH has been described in the older literature in patients treated with pulsatile GnRH, including reports of treatment failure attributed to neutralizing antibodies in hypogonadotropic azoospermic men. This is an inherent risk of administering a peptide hormone repeatedly over long periods and is one of the differences between a single diagnostic exposure and chronic use.

In ovulation induction, the relevant risks belong to the clinical context rather than the molecule: multiple follicular development, multiple gestation and ovarian hyperstimulation. The published pulsatile GnRH experience is notable precisely because monofollicular ovulation predominated, which lowers those risks relative to injectable gonadotropins, but that outcome depended on careful monitoring by a fertility service.

Products prepared by compounding pharmacies are not FDA-approved, which means identity, potency and sterility rest on the facility's own quality systems rather than on an approved application. Material sold as a research chemical carries no such assurance at all and is not intended for human use. Anyone considering gonadorelin for any purpose should do so under the care of a licensed clinician.

Is gonadorelin prohibited in sport?

Yes, for male athletes. Under the World Anti-Doping Code International Standard Prohibited List, gonadotropin-releasing hormone and its agonist analogues appear in category S2, peptide hormones, growth factors, related substances and mimetics. Within the testosterone-stimulating peptides provision at S2.2.1, GnRH (gonadorelin) and agonists including buserelin, deslorelin, goserelin, histrelin, leuprorelin, nafarelin and triptorelin are prohibited in males.

The listing is sex-specific because the prohibited effect is stimulation of endogenous testosterone production through the pituitary. Substances in S2 are prohibited at all times, meaning both in competition and out of competition, so there is no permitted off-season window. The 2026 Prohibited List took effect on January 1, 2026.

Two practical consequences follow. A compounded or unapproved source does not change anti-doping liability: athletes are responsible for what is in their samples regardless of how a substance was obtained. And legitimate medical need does not create an automatic exemption; it has to be handled in advance through a Therapeutic Use Exemption with the relevant anti-doping organization.

Because the list is revised annually, athletes and support personnel should check the current version published by WADA rather than relying on a summary, including this one.

Test your knowledge

Quick quiz · 6 questions

Frequently Asked Questions

Is gonadorelin the same thing as GnRH?
Yes. Gonadorelin is the pharmaceutical name for a synthetic version of gonadotropin-releasing hormone, also called LHRH. It has the same ten amino acid sequence as the hormone produced by hypothalamic neurons, which distinguishes it from modified analogues such as leuprorelin or triptorelin that were engineered to last far longer in the body.
Is gonadorelin FDA approved?
Not currently. Two human products containing it were approved in the United States, Factrel for diagnostic evaluation of pituitary gonadotropic function and Lutrepulse (approved in 1989) for ovulation induction in primary hypothalamic amenorrhea, and both are listed as discontinued in Drugs@FDA. Preparations made by compounding pharmacies are not FDA-approved products.
Why does continuous exposure to GnRH suppress hormones instead of raising them?
Because the pituitary responds to the pattern of the signal rather than to the total amount. Belchetz and colleagues showed in 1978 that intermittent GnRH delivery restored LH and FSH secretion in primates with hypothalamic lesions while continuous infusion did not, and that continuous exposure caused desensitization and down regulation of the release mechanism. That is the same biology exploited therapeutically by long-acting GnRH agonists in prostate cancer and endometriosis.
Does gonadorelin work as well as hCG for men on testosterone therapy?
No comparative trial answers that question. There is no published head-to-head study of gonadorelin against hCG for any men's health endpoint, and no randomized controlled trial establishing that gonadorelin preserves testicular function or fertility in men on exogenous testosterone. Clinical guidelines from the American Urological Association discuss hCG for men with fertility concerns and advise against testosterone monotherapy in men interested in current or future fertility. Any individual decision belongs with a physician who can monitor laboratory values.
Why did testosterone clinics start using gonadorelin at all?
Largely for regulatory reasons. On March 23, 2020, hCG transitioned to regulation as a biological product, which made it ineligible for the pharmacy compounding exemptions under sections 503A and 503B. A 2023 study in Sexual Medicine found that of 81 FDA-registered 503B outsourcing facilities approved to compound hCG and FSH, only five actually supplied hCG, and six of eight facilities that had stopped cited the 2020 change. Gonadorelin is a synthetic peptide rather than a biological product and remained available through compounding.
What is the strongest clinical evidence for gonadorelin?
Pulsatile pump therapy in people with a deficient hypothalamic signal. A 25-year single-center cohort of women with functional hypothalamic amenorrhea covering 66 patients, 82 treatments and 212 cycles reported a 96% ovulation rate per cycle with monofollicular ovulation in 75% of cycles, alongside high cumulative live birth rates and low multiple gestation rates. In men with gonadotropin deficiency, pulsatile GnRH has performed comparably to or better than combined gonadotropin therapy for inducing spermatogenesis, depending on the underlying diagnosis.
Is gonadorelin banned in sport?
It is prohibited in males at all times under WADA category S2.2.1 as a testosterone-stimulating peptide, alongside GnRH agonists such as leuprorelin and triptorelin. Obtaining it through a compounding pharmacy does not change that, and a documented medical need requires a Therapeutic Use Exemption granted in advance. Athletes should consult the current Prohibited List, which is revised each year.
Does the HHS peptide policy from October 2026 apply to gonadorelin?
No. The HHS enforcement discretion policy issued on October 28, 2026 covers 503A compounding of six named peptide bulk drug substances: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Gonadorelin is not on that list, and the policy explicitly does not grant FDA approval or establish safety and effectiveness for the peptides it does cover. Gonadorelin's compounding position rests on its separate history as an active ingredient of previously approved human drugs.

Sources

  1. Schally AV, Arimura A, Baba Y, Nair RM, Matsuo H, Redding TW, Debeljuk L (1971). Isolation and properties of the FSH and LH-releasing hormone. Biochemical and Biophysical Research Communications. (PubMed)
  2. Belchetz PE, Plant TM, Nakai Y, Keogh EJ, Knobil E (1978). Hypophysial responses to continuous and intermittent delivery of hypothalamic gonadotropin-releasing hormone. Science. (PubMed)
  3. Pimstone B, Epstein S, Hamilton SM, LeRoith D, Hendricks S (1977). Metabolic clearance and plasma half disappearance time of exogenous gonadotropin releasing hormone in normal subjects and in patients with liver disease and chronic renal failure. Journal of Clinical Endocrinology and Metabolism. (PubMed)
  4. Quaas P, Quaas AM, Fischer M, De Geyter C (2022). Use of pulsatile gonadotropin-releasing hormone (GnRH) in patients with functional hypothalamic amenorrhea (FHA) results in monofollicular ovulation and high cumulative live birth rates: a 25-year cohort. Journal of Assisted Reproduction and Genetics. (PubMed)
  5. Zhang J, Zhu Y, Zhang R, et al. (2024). Pulsatile Gonadotropin-Releasing Hormone Therapy Is Associated With Better Spermatogenic Outcomes than Gonadotropin Therapy in Patients With Pituitary Stalk Interruption Syndrome. Endocrine Practice. (PubMed)
  6. Borgert BJ, Bacchus MW, Hernandez AD, Potts SN, Campbell KJ (2023). The availability of gonadotropin therapy from FDA-approved pharmacies for men with hypogonadism and infertility. Sexual Medicine. (PMC)
  7. Akın O, Yavuz ST, Hacıhamdioğlu B, Sarı E, Gürsel O, Yeşilkaya E (2015). Anaphylaxis to gonadorelin acetate in a girl with central precocious puberty. Journal of Pediatric Endocrinology and Metabolism. (PubMed)
  8. US Food and Drug Administration (2020). Notice to Compounders: Changes that affect compounding as of March 23, 2020. FDA, Human Drug Compounding. (fda.gov)
  9. US Department of Health and Human Services (2026). HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. HHS. (hhs.gov)
  10. World Anti-Doping Agency (2026). The Prohibited List (International Standard, in force January 1, 2026). WADA. (wada-ama.org)
  11. Esteve Pharmaceuticals (2026). Gonadorelin 100 micrograms powder for solution for injection: Summary of Product Characteristics. electronic Medicines Compendium (UK). (medicines.org.uk)
  12. American Urological Association (2024). Evaluation and Management of Testosterone Deficiency: AUA Guideline. AUA Guidelines. (auanet.org)
  13. American Society of Health-System Pharmacists (2026). Drug Shortage Detail: Chorionic Gonadotropin (Human) for Injection. ASHP Drug Shortages. (ashp.org)
  14. Ferring Pharmaceuticals (2013). Multicenter, double-blind, randomized, placebo-controlled study of subcutaneous pulsatile GnRH via pump for ovulation induction in primary amenorrhea with hypogonadotropic hypogonadism. ClinicalTrials.gov, NCT01976728. (clinicaltrials.gov)
  15. Massachusetts General Hospital (2009). The Effects of 7 Days of Exogenous Pulsatile GnRH Treatment on the Pituitary-Gonadal Axis in Hypogonadotropic Hypogonadal Subjects. ClinicalTrials.gov, NCT00493961. (clinicaltrials.gov)

This content is for informational and educational purposes only. It does not constitute medical advice. Consult a healthcare professional before making any decisions. Read our full medical disclaimer

GHK-Cu
GHK-Cu
Powerful Anti-Aging →